CCWM
GMAB icon

Cassaday & Co Wealth Management’s Genmab GMAB Stock Holding History

Cassaday & Co Wealth Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248 Hold
9
– – ﹤0.01% 1202
2026
Q1 		$242 Buy
+9
New +$270 ﹤0.01% 1251

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cassaday & Co Wealth Management's GMAB Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Genmab (GMAB) position steady in Q2 2026 at 9 shares worth $248. The position accounts for ﹤0.01% of the portfolio, ranked #1202.

Cassaday & Co Wealth Management first reported a position in GMAB in Q1 2026 and has held it in 2 quarters since. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Cassaday & Co Wealth Management held 9 shares of Genmab worth $248 as of Q2 2026.
  • Cassaday & Co Wealth Management left its Genmab share count unchanged in Q2 2026.
  • Genmab made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1202 holding.
  • Cassaday & Co Wealth Management first reported a position in Genmab in Q1 2026 and has held it in 2 quarters since.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.